Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma

Neoplasia (United States)

Volumn 15, Issue 3, 2013, Pages 305-314

  Tano, Tomoyuki ^a   Okamoto, Masato ^b   Kan, Shin ^c   Nakashiro, Koh Ichi ^a   Shimodaira, Shigetaka ^d   Koido, Shigeo ^e   Homma, Sadamu ^e   Sato, Mitsunobu ^f   Fujita, Tomonobu ^b   Kawakami, Yutaka ^b   Hamakawa, Hiroyuki ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d SHINSHU UNIVERSITY HOSPITAL   (Japan)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION;

EID: 84874615958     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121528     Document Type: Article

References (35)

1. Walsh JE, Lathers DM, Chi AC, Gillespie MB, Day TA, and Young MR (2007). Mechanisms of tumor growth and metastasis in head and neck squamous cell carcinoma. Curr Treat Options Oncol 8, 227-238.
2. Whiteside TL (2010). Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther 10, 1019-1035.
3. Allen CT, Judd NP, Bui JD, and Uppaluri R (2012). The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope 122, 144-157.
4. Ostrand-Rosenberg S (2010). Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 59, 1593-1600.
5. Gastman BR, Atarashi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, and Whiteside TL (1999). Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59, 5356-5364.
6. Kim JW, Tsukishiro T, Johnson JT, and Whiteside TL (2004). Expression of pro-and antiapoptotic proteins in circulating CD8+ T cells of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 10, 5101-5110.
7. + T cell survival by up-regulating Bcl-xL. J Immunol 176, 6709-6716.
8. Liphaus BL, Kiss MH, Carrasco S, and Goldenstein-Schainberg C (2007). Increased Fas and Bcl-2 expression on peripheral mononuclear cells from patients with active juvenile-onset systemic lupus erythematosus. J Rheumatol 34, 1580-1584.
9. Pillet AH, Thèze J, and Rose T (2011). Interleukin (IL)-2 and IL-15 have different effects on human natural killer lymphocytes. Hum Immunol 72, 1013-1017.
10. DeBarros A, Chaves-Ferreira M, d'Orey F, Ribot JC, and Silva-Santos B (2011). CD70-CD27 interactions provide survival and proliferative signals that regulate T cell receptor-driven activation of human γδ peripheral blood lymphocytes. Eur J Immunol 41, 195-201.
11. + T cell longevity and avoidance of TRAIL-mediated apoptosis. Proc Natl Acad Sci USA 105, 5201-5206.
12. Kim H, Rafiuddin-Shah M, Tu HC, Jeffers JR, Zambetti GP, Hsieh JJ, and Cheng EH (2006). Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 8, 1348-1358.
13. Homma A, Furuta Y, Oridate N, Nakano Y, Kohashi G, Yagi K, Nagahashi T, Yagi K, Nagahashi T, Fukuda S, et al. (1999). Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Clin Cancer Res 5, 801-806.
14. Gallo O, Boddi V, Calzolari A, Simonett L, Trovati M, and Bianchi S (1996). Bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy. Clin Cancer Res 2, 261-267.
15. Green VL, Irune E, Prasai A, Alhamarneh O, Greenman J, and Stafford ND (2012). Serum IL10, IL12 and circulating CD4+CD25high T regulatory cells in relation to long-term clinical outcome in head and neck squamous cell carcinoma patients. Int J Oncol 40, 833-839.
16. Chang KP, Chang YT, Wu CC, Liu YL, Chen MC, Tsang NM, Hsu CL, Chang YS, and Yu JS (2011). Multiplexed immunobead-based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival. Head Neck 33, 8868-8897.
17. Uppaluri R, Dunn GP, and Lewis JS Jr (2008). Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun 8, 16.
18. Kikkawa F, Kawai M, Oguchi H, Kojima M, Ishikawa H, Iwata M, Maeda O, Tomoda Y, Arii Y, and Kuzuya K (1993). Randomised study of immunotherapy with OK-432 in uterine cervical carcinoma. Eur J Cancer 29, 1542-1546.
19. Maehara Y, Okuyama T, Kakeji Y, Baba H, Furusawa M, and Sugimachi K (1994). Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg 168, 36-40.
20. Boyum A (1968). Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest 97(suppl), 77-89.
21. Messina E, Gazzaniga P, Micheli V, Guaglianone MR, Barbato S, Morrone S, Frati L, Aglianò AM, and Giacomello A (2004). Guanine nucleotide depletion triggers cell cycle arrest and apoptosis in human neuroblastoma cell lines. Int J Cancer 108, 812-817.
22. Nakashiro K, Kawamata H, Hino S, Uchida D, Miwa Y, Hamano H, Omotehara F, Yoshida H, and Sato M (1998). Down-regulation of TSC-22 (transforming growth factor β-stimulated clone 22) markedly enhances the growth of a human salivary gland cancer cell line in vitro and in vivo. Cancer Res 86, 549-555.
23. Aramaki M, Kim YI, Shimoda K, Nakashima K, Okada K, and Kobayashi M (1994). Induction by OK-432 of lymphokine activated killer precursor cells in hepatocellular carcinoma. Hepatogastroenterology 4, 363-366.
24. Timonen T and Saksela E (1977). A simplified isotope release assay for cell-mediated cytotoxicity against anchorage dependent target cells. J Immunol Methods 18, 123-132.
25. Sato M, Harada K, Yoshida H, Yura Y, Azuma M, Iga H, Bando T, Kawamata H, and Takegawa Y (1997). Therapy for oral squamous cell carcinoma by tegafur and streptococcal agent OK-432 in combination with radiotherapy: association of the therapeutic effect with differentiation and apoptosis in the cancer cells. Apoptosis 2, 227-238.
26. Okamoto M, Oshikawa T, Tano T, Ohe G, Furuichi S, Nishikawa H, Ahmed SU, Akashi S, Miyake K, Takeuchi O, et al. (2003). Involvement of Toll-like receptor 4 signaling in interferon-γ production and antitumor effect by strepto-coccal agent OK-432. J Natl Cancer Inst 95, 316-326.
27. Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU, Takeda K, Akira S, Ryoma Y, Moriya Y, et al. (2004). Expression of Toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res 64, 5461-5470.
28. Oshimi K, Kano S, Takaku F, and Okumura K (1980). Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432. J Natl Cancer Inst 65, 1265-1269.
29. Misaki T, Watanabe Y, Iida Y, Hidaka A, Kasagi K, Fukushima H, and Konishi J (1992). Recruitment of T lymphocytes and induction of tumor necrosis factor in thyroid cancer by a local immunotherapy. Cancer Immunol Immunother 35, 92-96.
30. Fujimoto T, Duda RB, Azilvasi A, Chen X, Mai M, and O'Donnell MA (1997). Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. J Immunol 158, 5619-5626.
31. Ahmed SU, Okamoto M, Oshikawa T, Tano T, Sasai A, Kan S, Hiroshima T, Ohue H, Moriya Y, Ryoma Y, et al. (2004). Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of Toll-like receptor 4. J Immunother 27, 432-441.
32. Okamoto M, Oshikawa T, Tano T, Ahmed SU, Kan S, Sasai A, Akashi S, Miyake K, Moriya Y, Ryoma Y, et al. (2006). Mechanism of anticancer host response induced by OK-432, a streptococcal preparation, mediated by phagocytosis and Toll-like receptor 4 signaling. J Immunother 29, 78-86.
33. Matsushita K, Takenouchi T, Kobayashi S, Hayashi H, Okuyama K, and Ochiai T (1996). HLA-DR antigen expression on colorectal carcinomas: influence of expression by IFN-γ in situ and its association with tumour progression. Br J Cancer 73, 644-648.
34. Czystowska M, Szczepanski MJ, Szajnik M, Quadrini K, Brandwein H, Hadden JW, and Whiteside TL (2011). Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic. Cancer Immunol Immunother 60, 495-506.
35. Czystowska M, Han J, Szczepanski MJ, Szajnik M, Quadrini K, Brandwein H, Hadden JW, Signorelli K, and Whiteside TL (2009). IRX-2, a novel immune-therapeutic, protects human T cells from tumor-induced cell death. Cell Death Differ 16, 708-718.